JP2017178948A5 - - Google Patents

Download PDF

Info

Publication number
JP2017178948A5
JP2017178948A5 JP2017086446A JP2017086446A JP2017178948A5 JP 2017178948 A5 JP2017178948 A5 JP 2017178948A5 JP 2017086446 A JP2017086446 A JP 2017086446A JP 2017086446 A JP2017086446 A JP 2017086446A JP 2017178948 A5 JP2017178948 A5 JP 2017178948A5
Authority
JP
Japan
Prior art keywords
methyl
compound
composition
etidocaine
trimethyltocainide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017086446A
Other languages
English (en)
Japanese (ja)
Other versions
JP6530005B2 (ja
JP2017178948A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2017178948A publication Critical patent/JP2017178948A/ja
Publication of JP2017178948A5 publication Critical patent/JP2017178948A5/ja
Application granted granted Critical
Publication of JP6530005B2 publication Critical patent/JP6530005B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017086446A 2009-07-10 2017-04-25 抗炎症剤としての恒久的に荷電したナトリウムおよびカルシウムチャンネルブロッカー Expired - Fee Related JP6530005B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22451209P 2009-07-10 2009-07-10
US61/224,512 2009-07-10

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2012519763A Division JP6205133B2 (ja) 2009-07-10 2010-07-09 抗炎症剤としての恒久的に荷電したナトリウムおよびカルシウムチャンネルブロッカー

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019091784A Division JP6845280B2 (ja) 2009-07-10 2019-05-15 抗炎症剤としての恒久的に荷電したナトリウムおよびカルシウムチャンネルブロッカー

Publications (3)

Publication Number Publication Date
JP2017178948A JP2017178948A (ja) 2017-10-05
JP2017178948A5 true JP2017178948A5 (enExample) 2017-11-16
JP6530005B2 JP6530005B2 (ja) 2019-06-12

Family

ID=43429565

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2012519763A Expired - Fee Related JP6205133B2 (ja) 2009-07-10 2010-07-09 抗炎症剤としての恒久的に荷電したナトリウムおよびカルシウムチャンネルブロッカー
JP2017086446A Expired - Fee Related JP6530005B2 (ja) 2009-07-10 2017-04-25 抗炎症剤としての恒久的に荷電したナトリウムおよびカルシウムチャンネルブロッカー
JP2019091784A Active JP6845280B2 (ja) 2009-07-10 2019-05-15 抗炎症剤としての恒久的に荷電したナトリウムおよびカルシウムチャンネルブロッカー
JP2021028224A Pending JP2021098713A (ja) 2009-07-10 2021-02-25 抗炎症剤としての恒久的に荷電したナトリウムおよびカルシウムチャンネルブロッカー

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2012519763A Expired - Fee Related JP6205133B2 (ja) 2009-07-10 2010-07-09 抗炎症剤としての恒久的に荷電したナトリウムおよびカルシウムチャンネルブロッカー

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019091784A Active JP6845280B2 (ja) 2009-07-10 2019-05-15 抗炎症剤としての恒久的に荷電したナトリウムおよびカルシウムチャンネルブロッカー
JP2021028224A Pending JP2021098713A (ja) 2009-07-10 2021-02-25 抗炎症剤としての恒久的に荷電したナトリウムおよびカルシウムチャンネルブロッカー

Country Status (7)

Country Link
US (5) US20120172429A1 (enExample)
EP (3) EP2451944A4 (enExample)
JP (4) JP6205133B2 (enExample)
CN (1) CN102725401A (enExample)
AU (4) AU2010271269B2 (enExample)
CA (2) CA3027255C (enExample)
WO (1) WO2011006073A1 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007322033B2 (en) 2006-11-20 2013-07-11 President And Fellows Of Harvard College Methods, compositions, and kits for treating pain and pruritis
JP6205133B2 (ja) * 2009-07-10 2017-09-27 プレジデント アンド フェローズ オブ ハーバード カレッジ 抗炎症剤としての恒久的に荷電したナトリウムおよびカルシウムチャンネルブロッカー
WO2012012498A2 (en) * 2010-07-20 2012-01-26 Pulmatrix, Inc. Use of trp channel agonists to treat infections
WO2012030645A1 (en) 2010-08-30 2012-03-08 Pulmatrix, Inc. Respirably dry powder comprising calcium lactate, sodium chloride and leucine
BR112013007304B1 (pt) 2010-09-29 2021-12-14 Pulmatrix, Inc. Pós secos de cátion de metal monovalente para inalação
WO2012084869A1 (en) * 2010-12-22 2012-06-28 Galderma Research & Development Modulators of trpa1 for the treatment of rosacea
US20140031341A1 (en) * 2010-12-22 2014-01-30 Universitat Munster Modulators and methods for the treatment of rosacea
MX386293B (es) 2011-02-18 2025-03-18 Libertas Bio Inc Compuestos de aminoindano y su uso en el tratamiento del dolor.
JP6495654B2 (ja) 2011-10-24 2019-04-03 アサナ バイオサイエンシズ,リミティド ライアビリティ カンパニー シクロヘキシルアミン類
WO2013141202A1 (ja) * 2012-03-21 2013-09-26 独立行政法人国立精神・神経医療研究センター 筋増加剤、及び筋増加物質のスクリーニング方法
WO2014028675A1 (en) 2012-08-15 2014-02-20 Endo Pharmaceuticals Inc. Use of aminoindane compounds in treating overactive bladder and interstitial cystitis
CA2900710C (en) 2013-02-08 2023-08-08 General Mills, Inc. Reduced sodium food products
AU2014248455B2 (en) 2013-04-01 2018-12-06 Pulmatrix Operating Company, Inc. Tiotropium dry powders
JP6393680B2 (ja) * 2013-05-23 2018-09-19 学校法人近畿大学 T型カルシウムチャネル阻害剤
JP2016524609A (ja) * 2013-05-24 2016-08-18 ネステク ソシエテ アノニム メントール及び/又はイシリンを用いるうつ病の処置又は予防
EP3003292B1 (en) * 2013-05-24 2019-03-20 Nestec S.A. Treatment or prevention of non-inflammatory neuronal damage from brain trauma and strokes using menthol, linalool and/or icilin
US9700549B2 (en) 2013-10-03 2017-07-11 David Wise Compositions and methods for treating pelvic pain and other conditions
KR102597910B1 (ko) 2015-03-26 2023-11-02 재클린 엠. 이베르센 숙취상태와 연관된 증상들을 억제하기 위한 방법 및 조성물
KR20180069782A (ko) 2015-08-03 2018-06-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 하전 이온 채널 블록커 및 이용 방법
CN106214670B (zh) * 2016-07-25 2020-12-29 上海璃道医药科技有限公司 酰胺类药物的用途
CN106220562B (zh) * 2016-07-29 2019-10-01 上海璃道医药科技有限公司 两种喹啉环类药物的新用途
CN106892875B (zh) * 2016-11-11 2018-03-02 杭州唯铂莱生物科技有限公司 钙离子通道阻滞剂化合物及其制备方法和应用
EP3762034B1 (en) 2018-03-05 2025-08-27 Wylder Nation Foundation A fatty acid amide hydrolase (faahi) inhibitor for use in inhibiting the cellular accumulation of a sphingolipid in a subject that has lysosomal storage disease or disorder
US10744087B2 (en) 2018-03-22 2020-08-18 Incarda Therapeutics, Inc. Method to slow ventricular rate
CN108467337B (zh) * 2018-04-23 2020-12-15 中国科学院烟台海岸带研究所 一种倍半萜烯醇类化合物及其制备和应用
CN108324685A (zh) * 2018-04-28 2018-07-27 武汉田田药业有限公司 一种盐酸氟桂利嗪口服溶液的生产工艺
US12138274B2 (en) 2018-11-08 2024-11-12 Board Of Regents Of The University Of Nebraska Compositions and methods for the treatment of peripheral artery disease and cardiopulmonary diseases
US10828287B2 (en) 2019-03-11 2020-11-10 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
AU2020235888A1 (en) 2019-03-11 2021-09-30 Nocion Therapeutics, Inc. Charged ION channel blockers and methods for use
US10934263B2 (en) 2019-03-11 2021-03-02 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
MX2021010869A (es) 2019-03-11 2022-01-19 Nocion Therapeutics Inc Bloqueadores de canales iónicos sustituidos por éster y métodos para su uso.
US10780083B1 (en) 2019-03-11 2020-09-22 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
EP4003302A1 (en) 2019-07-31 2022-06-01 Journey Medical Corporation Compositions and methods and uses thereof
AU2020323594B2 (en) 2019-08-01 2022-02-03 Incarda Therapeutics, Inc. Antiarrhythmic formulation
US11007185B2 (en) 2019-08-01 2021-05-18 Incarda Therapeutics, Inc. Antiarrhythmic formulation
US10933055B1 (en) 2019-11-06 2021-03-02 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
CN114828845A (zh) 2019-11-06 2022-07-29 诺西恩医疗公司 带电的离子通道阻滞剂及其使用方法
CN119118953A (zh) * 2020-03-11 2024-12-13 诺西恩医疗公司 带电的离子通道阻滞剂及其使用方法
US12162851B2 (en) 2020-03-11 2024-12-10 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
WO2023064489A1 (en) * 2021-10-14 2023-04-20 Galileo Biosystems, Inc. Aryl hydrocarbon receptor (ahr) modulators and therapeutic uses thereof
EP4531831A1 (en) * 2022-05-31 2025-04-09 Vivasor, Inc. Method for treating inflammatory dysfunction of the oral mucosa
CN114853630B (zh) * 2022-06-07 2023-06-27 温州医科大学 一种2,6-二苯亚甲基环己酮肟类化合物及其制备方法和应用

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE151036C (enExample)
DE150423C (enExample)
US812554A (en) 1905-11-08 1906-02-13 Hoechst Ag Alkamin esters of para-aminobenzoic acid.
US1889645A (en) 1930-12-22 1932-11-29 Winthrop Chem Co Inc Beta-dimethylaminoethyl ester of para-butylamino-benzoic acid
US2441498A (en) 1943-07-15 1948-05-11 Astra Apotekarnes Kem Fab Alkyl glycinanilides
US2689248A (en) 1950-06-17 1954-09-14 Sterling Drug Inc Tertiary-aminoalkyl 4-amino-2-alkoxybenzoates and their synth esis
US2799679A (en) 1955-04-28 1957-07-16 Bofors Ab Process of preparing amides of heterocyclic carboxylic acids
US2883271A (en) 1956-11-23 1959-04-21 Phillips Petroleum Co Safety system for combustion process
US2955111A (en) 1957-01-28 1960-10-04 Bofors Ab Synthesis of n-alkyl-piperidine and n-alkyl-pyrrolidine-alpha-carboxylic acid amides
US3160662A (en) 1957-06-26 1964-12-08 Astra Apotekarnes Kem Fab Lower alkylaminoacyl amide anesthetics
NL281394A (enExample) 1961-07-25
DE1251764B (de) 1965-08-18 1967-10-12 C H Boehnnger Sohn Ingelheim/ Rhein Verfahren zur Herstellung von antimikrobiell wirksamen 12 3,4-Tetra hydro 9 -ammo acridmiumverbmdungen
US3812147A (en) 1970-12-22 1974-05-21 Astra Pharma Prod Acylxylidide local anaesthetics
US3931195A (en) 1971-03-03 1976-01-06 Mead Johnson & Company Substituted piperidines
BE786875A (fr) 1971-07-28 1973-01-29 Astra Pharma Prod Amide, methode pour sa preparation et ses compositions therapeutiques
US3773939A (en) 1971-11-24 1973-11-20 Janssen Pharmaceutica Nv N-arallyl-n'-aralkyl piperazine pharmaceutical compositions
US4069309A (en) 1972-09-19 1978-01-17 Avon Products, Inc. Cationic skin substantive sunscreen composition and method
US3900481A (en) 1974-04-01 1975-08-19 Riker Laboratories Inc Derivatives of pyrrolidine and piperidine
CS195321B2 (en) 1975-12-23 1980-01-31 Ciba Geigy Ag Plant growth suppressing agents
US4070347A (en) 1976-08-16 1978-01-24 Alza Corporation Poly(orthoester) co- and homopolymers and poly(orthocarbonate) co- and homopolymers having carbonyloxy functionality
DE2915250A1 (de) 1979-04-14 1980-10-30 Basf Ag Salze von alpha -aminoacetaniliden
US4293539A (en) 1979-09-12 1981-10-06 Eli Lilly And Company Controlled release formulations and method of treatment
US4877805A (en) 1985-07-26 1989-10-31 Kligman Albert M Methods for treatment of sundamaged human skin with retinoids
US4757128A (en) 1986-08-01 1988-07-12 Massachusetts Institute Of Technology High molecular weight polyanhydride and preparation thereof
US5169637A (en) 1983-03-24 1992-12-08 The Liposome Company, Inc. Stable plurilamellar vesicles
DE3379266D1 (en) 1983-08-01 1989-04-06 Astra Laekemedel Ab L-n-n-propylpipecolic acid-2,6-xylidide and method for preparing the same
CA1237671A (en) 1983-08-01 1988-06-07 Michael W. Fountain Enhancement of pharmaceutical activity
US5409704A (en) 1985-06-26 1995-04-25 The Liposome Company, Inc. Liposomes comprising aminoglycoside phosphates and methods of production and use
US4975282A (en) 1985-06-26 1990-12-04 The Liposome Company, Inc. Multilamellar liposomes having improved trapping efficiencies
US5023087A (en) 1986-02-10 1991-06-11 Liposome Technology, Inc. Efficient method for preparation of prolonged release liposome-based drug delivery system
IE60901B1 (en) 1986-08-21 1994-08-24 Vestar Inc Improved treatment of systemic fungal infections with phospholipid particles encapsulating polyene antifungal antibiotics
US5049388A (en) 1986-11-06 1991-09-17 Research Development Foundation Small particle aerosol liposome and liposome-drug combinations for medical use
CA1319144C (en) 1986-11-14 1993-06-15 Quirico Branca Tetrahydronaphthalene derivatives
US5032582A (en) 1987-02-27 1991-07-16 Liposome Technology, Inc. Method for treating fungal infections with amphotericin B/cholesterol sulfate composition
US4994213A (en) 1988-05-17 1991-02-19 Liposome Technology, Inc. Method of preparing lipid structures
US5082866A (en) 1988-06-01 1992-01-21 Odontex, Inc. Biodegradable absorption enhancers
US4980378A (en) 1988-06-01 1990-12-25 Odontex, Inc. Biodegradable absorption enhancers
US5194581A (en) 1989-03-09 1993-03-16 Leong Kam W Biodegradable poly(phosphoesters)
US5194266A (en) 1989-08-08 1993-03-16 Liposome Technology, Inc. Amphotericin B/cholesterol sulfate composition and method
US5356633A (en) 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
AU657961B2 (en) 1991-04-19 1995-03-30 Nexstar Pharmaceuticals, Inc. Pharmaceutical formulation and process
US5176907A (en) 1991-08-13 1993-01-05 The Johns Hopkins University School Of Medicine Biocompatible and biodegradable poly (phosphoester-urethanes)
GR1002207B (en) 1992-08-06 1996-03-27 Johnson & Johnson Consumer Skin care compositions containing imidazoles.
US5552155A (en) 1992-12-04 1996-09-03 The Liposome Company, Inc. Fusogenic lipsomes and methods for making and using same
US5480971A (en) * 1993-06-17 1996-01-02 Houghten Pharmaceuticals, Inc. Peralkylated oligopeptide mixtures
US6051576A (en) 1994-01-28 2000-04-18 University Of Kentucky Research Foundation Means to achieve sustained release of synergistic drugs by conjugation
US5591317A (en) 1994-02-16 1997-01-07 Pitts, Jr.; M. Michael Electrostatic device for water treatment
US5716622A (en) 1995-01-06 1998-02-10 The Rockefeller University Functionally active regions of signal transducer and activators of transcription
US5783683A (en) 1995-01-10 1998-07-21 Genta Inc. Antisense oligonucleotides which reduce expression of the FGFRI gene
AU5938996A (en) 1995-06-07 1996-12-30 Nexstar Pharmaceuticals, Inc. Method for encapsulating pharmaceutical materials
US5747470A (en) 1995-06-07 1998-05-05 Gen-Probe Incorporated Method for inhibiting cellular proliferation using antisense oligonucleotides to gp130 mRNA
US6413961B1 (en) 1995-12-12 2002-07-02 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation
SE508357C2 (sv) 1996-01-02 1998-09-28 Kay Laserow Mätinstrument för mätning av smärta jämte ett förfarande för att med ett mätinstrument mäta smärta
WO1998024428A1 (en) 1996-12-02 1998-06-11 Brigham & Women's Hospital, Inc. Long-acting local anesthetics
SE9604751D0 (sv) 1996-12-20 1996-12-20 Astra Ab New therapy
US5837713A (en) 1997-02-26 1998-11-17 Mayo Foundation For Medical Education And Research Treatment of eosinophil-associated pathologies by administration of topical anesthetics and glucocorticoids
US6008318A (en) 1997-06-18 1999-12-28 Guilford Pharmaceuticals Inc. Two-stage solution polymerization of high molecular weight poly(phosphoesters)
US6028163A (en) 1997-06-27 2000-02-22 Guilford Pharmaceuticals Inc. Solution polymerization of high molecular weight poly(phosphoesters) in toluene
AU7937298A (en) 1997-07-08 1999-02-08 Ono Pharmaceutical Co. Ltd. Amino acid derivatives
TW536401B (en) 1997-09-03 2003-06-11 Cardiome Pharma Corp A pharmaceutical composition of N,N-bis(phenylcarbamoylmethyl)dimethylammomum chloride and derivatives for the treatment of pain
US6623040B1 (en) 1997-09-03 2003-09-23 Recot, Inc. Method for determining forced choice consumer preferences by hedonic testing
US6083996A (en) 1997-11-05 2000-07-04 Nexmed Holdings, Inc. Topical compositions for NSAI drug delivery
BR9911094A (pt) * 1998-06-09 2001-10-30 Nortran Pharmaceuticals Inc Composições e métodos para o tratamento detosse
US6153212A (en) 1998-10-02 2000-11-28 Guilford Pharmaceuticals Inc. Biodegradable terephthalate polyester-poly (phosphonate) compositions, articles, and methods of using the same
US6103255A (en) 1999-04-16 2000-08-15 Rutgers, The State University Porous polymer scaffolds for tissue engineering
US6118020A (en) 1999-05-19 2000-09-12 Nexmed Holdings, Inc. Crystalline salts of dodecyl 2-(N,N-dimethylamino)-propionate
US6355637B1 (en) * 1999-10-01 2002-03-12 Advanced Medicine, Inc. Local anesthetic compounds
HUP0204014A3 (en) 1999-12-15 2005-04-28 Ucb Farchim Sa Quaternary salts of-n-substituted cyclic or acyclic amines and their use as pharmaceutical compositions
CZ20022095A3 (cs) 1999-12-15 2003-02-12 Ucb Farchim S. A. Cyklická kvarterní amoniová sloučenina pro použití při léčbě a/nebo prevenci kašle u teplokrevného živočicha a farmaceutický prostředek ji obsahující
WO2001045678A2 (de) 1999-12-21 2001-06-28 Id Pharma Gmbh Arzneimittel, verfahren zu dessen herstellung und dessen verwendung
WO2001083828A1 (en) 2000-05-04 2001-11-08 Dzgenes, Llc TGFβ-RII PROMOTER POLYMORPHISMS
IL153574A0 (en) * 2000-06-23 2003-07-06 Mayo Foundation Methods of treating neutrophil-related diseases with topical anesthetics
DE10039449A1 (de) 2000-08-11 2003-07-24 Id Pharma Gmbh I Ins Verwendung einer lokalanästhetikumhaltigen Zusammensetzung zur Behandlung von Hyperalgesien
US6766319B1 (en) 2000-10-31 2004-07-20 Robert J. Might Method and apparatus for gathering and evaluating information
US6884782B2 (en) 2000-11-08 2005-04-26 Amgen Inc. STAT modulators
US20030152637A1 (en) 2001-01-25 2003-08-14 Mark Chasin Local anesthetic, and method of use
US20040146590A1 (en) 2001-03-22 2004-07-29 Iadarola Michael J Molecular neurochirurgie for pain control administering locally capsaicin or resinferatoxin
CA2446060A1 (en) 2001-05-07 2002-11-14 Corium International Compositions and delivery systems for administration of a local anesthetic agent
CA2450769A1 (en) 2001-06-15 2002-12-27 Vertex Pharmaceuticals Incorporated 5-(2-aminopyrimidin-4-yl) benzisoxazoles as protein kinase inhibitors
ITMI20012025A1 (it) 2001-09-28 2003-03-28 Dompe Spa Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono
US7585511B2 (en) 2002-08-02 2009-09-08 Universite Libre De Bruxelles Apolipoprotein L-I and/or derivated polypeptide for the treatment of and/or the prevention of diseases induced by trypanosoma
ES2535045T3 (es) 2003-04-10 2015-05-04 Vanderbilt Royalty Sub L.P. Usos y composiciones para administración de capsaicina
US20040220187A1 (en) * 2003-04-22 2004-11-04 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a sodium ion channel blocker for the treatment of pain, inflammation or inflammation mediated disorders
US20060135506A1 (en) 2003-04-22 2006-06-22 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders
ES2223277B1 (es) 2003-06-19 2006-03-01 Fernando Bouffard Fita Composicion anestesica para administracion topica.
US8361467B2 (en) 2003-07-30 2013-01-29 Depuy Spine, Inc. Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints
NO20034069L (no) 2003-09-12 2005-03-14 Aximed As Fremstilling og bruk av capsaicinderivater
US20070149469A1 (en) 2003-10-02 2007-06-28 Christian Korherr Medical use of tbk-1 or of inhibitors thereof
US20050142596A1 (en) 2003-11-14 2005-06-30 Krolewski Andrzej S. Methods of diagnosing renal and cardiovascular disease
MXPA06006460A (es) 2003-12-11 2006-08-23 Univ Texas Compuestos para el tratamiento de enfermedades proliferativas celulares.
WO2005089206A2 (en) 2004-03-13 2005-09-29 Irm Llc Modulators of ion channel trpa1
US7161034B2 (en) 2004-04-20 2007-01-09 Dade Behring Inc. Lidocaine analogs and methods of making and using same
US20060106020A1 (en) 2004-04-28 2006-05-18 Rodgers James D Tetracyclic inhibitors of Janus kinases
JP5148271B2 (ja) 2004-06-02 2013-02-20 ニューロジズエックス,インコーポレーテッド 疼痛処置のためのカプサイシノイド、局所麻酔薬および/または鎮痒薬を含有する処方物
ES2651021T3 (es) 2004-07-24 2018-01-23 Laboratorios Del Dr. Esteve, S.A. Uso de compuestos activos sobre el receptor sigma para el tratamiento de alodinia mecánica
ITMI20041566A1 (it) 2004-07-30 2004-10-30 Indena Spa "trpv1 agonisti, formulazioni che li contengono e loro usi"
JP2008513445A (ja) * 2004-09-20 2008-05-01 コラス ファーマ インコーポレイテッド 吸入による送達で治療効果のある薬剤の許容性の改善方法
US7947682B2 (en) 2004-12-29 2011-05-24 University Of Southern California Substituted N′-pyrrolo[1,2-a]quinoxalin-4-yl-hydrazides as anti-cancer agents
US20060134008A1 (en) 2004-12-16 2006-06-22 Daniel Deaver Compositions and methods for pulmonary conditions
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
CA2621261C (en) 2005-09-22 2014-05-20 Incyte Corporation Azepine inhibitors of janus kinases
EP2982679A1 (en) 2005-10-12 2016-02-10 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
SG10202003901UA (en) 2005-12-13 2020-05-28 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
KR20080089416A (ko) * 2005-12-21 2008-10-06 페인셉터 파마 코포레이션 개폐 이온 통로를 조절하기 위한 조성물 및 방법
GB0526244D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
EP1867338A1 (en) 2006-05-30 2007-12-19 Université Libre De Bruxelles Pharmaceutical composition comprising apolipoproteins for the treatment of human diseases
AU2007322033B2 (en) 2006-11-20 2013-07-11 President And Fellows Of Harvard College Methods, compositions, and kits for treating pain and pruritis
CA2673038C (en) 2006-12-22 2015-12-15 Incyte Corporation Substituted tricyclic heteroaryl compounds as janus kinase inhibitors
WO2009026107A1 (en) 2007-08-17 2009-02-26 Portola Pharmaceuticals, Inc. Protein kinase inhibitors
CN101156851A (zh) * 2007-09-27 2008-04-09 刘全胜 盐酸尼卡地平分散片及其制备方法
EP2271329A4 (en) * 2008-03-11 2013-01-09 Harvard College METHOD, COMPOSITIONS AND SETS FOR TREATING PAIN AND PRURITIS
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
AU2009238590A1 (en) 2008-04-22 2009-10-29 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
AU2009268841B2 (en) 2008-07-08 2014-02-06 Board Of Regents, The University Of Texas System Novel inhibitors of proliferation and activation of signal transducer and activator of transcription (STATS)
DE102008037682A1 (de) * 2008-08-14 2010-04-08 Strackharn, Klaus, Dr.med. Verwendung äquipotenter Dosierungen von Lokalanästetika oder Derivaten davon zur Therapie chronischer Schmerzen
CN101347427A (zh) * 2008-09-22 2009-01-21 北京理工大学 一种沙坦化合物或其可药用盐和钙通道阻断剂或可药用盐的复方
CL2009001884A1 (es) 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
WO2010042543A2 (en) 2008-10-06 2010-04-15 Idera Pharmaceuticals, Inc. Use of inhibitors of toll-like receptors in the prevention and treatment of hypercholesterolemia and hyperlipidemia and diseases related thereto
WO2010111471A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP6205133B2 (ja) * 2009-07-10 2017-09-27 プレジデント アンド フェローズ オブ ハーバード カレッジ 抗炎症剤としての恒久的に荷電したナトリウムおよびカルシウムチャンネルブロッカー
US9023355B2 (en) 2010-04-13 2015-05-05 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for treating renal disease
WO2011133474A2 (en) 2010-04-18 2011-10-27 Beth Israel Deaconess Medical Center Methods of predicting predisposition to or risk of kidney disease
EP2611448A1 (en) 2010-09-01 2013-07-10 Ambit Biosciences Corporation 7-cyclylquinazoline derivatives and methods of use thereof
US8822537B2 (en) 2012-09-27 2014-09-02 Achelios Therapeutics, Inc. Topical ketoprofen composition
KR20180069782A (ko) 2015-08-03 2018-06-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 하전 이온 채널 블록커 및 이용 방법

Similar Documents

Publication Publication Date Title
JP2017178948A5 (enExample)
JP2012500090A5 (enExample)
JP2015078230A5 (enExample)
HK1222297A1 (zh) 一种包含ampk激活剂及血清素活性制剂之医药组合物及其用途
JP2016147915A5 (enExample)
JP2015504081A5 (enExample)
WO2014209841A3 (en) Compounds for treating spinal muscular atrophy
JP2015527333A5 (enExample)
JP2010132695A5 (enExample)
JP2011037901A5 (enExample)
JP2016518337A5 (enExample)
JP2015525757A5 (enExample)
JP2015523407A5 (enExample)
CN108026053A8 (zh) 作为mIDH1抑制剂的稠合的咪唑类化合物
JP2015534562A5 (enExample)
JP2015537009A5 (enExample)
JP2014526468A5 (enExample)
JP2015533163A5 (enExample)
JP2016530291A5 (enExample)
MX2015015132A (es) Composiciones farmaceuticas inhalables y los dispositivos inhaladores que las contienen.
JP2015516419A5 (enExample)
JP2014080432A5 (enExample)
JP2013523758A5 (enExample)
JP2015512948A5 (enExample)
JP2012525422A5 (enExample)